Profile: TRACON Pharmaceuticals Inc (TCON.A)
15 Aug 2019
TRACON Pharmaceuticals, Inc., incorporated on October 28, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
DE-122 and TRC253
DE-122 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. DE DE-122 is in the randomized Phase II AVANTE trial for patients with wet AMD. TRC253 is a novel, orally bioavailable small molecule discovered and developed by Janssen that is a potent, high-affinity competitive inhibitor of the androgen receptor (AR). TRC253 is also a pan-inhibitor of multiple AR mutations, including the F876L mutation, and is under development for the treatment of men with prostate cancer. The AR F876L mutation results in an alteration in the ligand binding domain that confers resistance to current AR inhibitors. TRC253 also potently inhibits signalling through the wild type.
The Company is developing TRC105 for use in combination with agents that inhibit angiogenesis by targeting the VEGF pathway. VEGF is required for angiogenesis. TRC105 binds to the endoglin receptor at a precise location to inhibit endothelial cell activation and angiogenesis. TRC105 has been studied in over six completed Phase II clinical trials and approximately three completed Phase I clinical trials, and is being dosed in over five Phase II clinical trials. TRC105 is focused on approximately two orphan indications, gestational trophoblastic neoplasia (GTN) and angiosarcoma. The next tier of development includes ongoing Phase II trials in renal cell carcinoma, glioblastoma and hepatocellular carcinoma. The Company has produced formulations of TRC105 for development in ophthalmology, which are developed for the treatment of wet AMD, the cause of blindness in the Western world.
The Company's TRC205 is a humanized, deimmunized anti-endoglin antibody. TRC205 is being developed for the treatment of fibrotic diseases, including nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
The Company is developing TRC102 (methoxyamine hydrochloride) to reverse resistance to specific chemotherapeutics by inhibiting base excision repair (BER). TRC102 interrupts BER by binding within apurinic/apyrimidinic (AP) sites, converting the AP site to a substrate for the enzyme topoisomerase II, which cleaves TRC102-bound deoxy ribonucleic acid (DNA), resulting in an accumulation of DNA strand breaks that trigger cellular apoptosis or programmed cell death. TRC102 is being developed to reverse resistance to Temodar, an alkylating chemotherapeutic, as well as to Alimta and Fludara, two antimetabolite chemotherapeutics. TRC102 began Phase II development through a Phase II clinical trial that combines TRC102 in patients with mesothelioma, as well as a Phase II clinical trial of TRC102 in patients with glioblastoma.
The Company competes with Pfizer, Inc., Acceleron Pharma Inc., Amgen, Inc., MedImmune LLC, OncoMed Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Roche AG, Genfit Corp., Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Galmed Medical Research Ltd., Gilead Sciences, Inc., Immuron Ltd., Shire plc, Mochida Pharmaceutical Co., Ltd., NasVax Ltd., Raptor Pharmaceutical Corp., Takeda Pharmaceutical Company Limited, InterMune, Inc., Boehringer Ingelheim, Biogen Idec., Bristol-Myers Squibb, Celgene Corporation, Fibrogen, Inc., Gilead, Janssen Pharmaceuticals Inc., Novartis AG, Sanofi S.A, Tesaro, Inc. and AbbVie Inc.
TRACON Pharmaceuticals Inc
4350 La Jolla Village Dr Ste 800
SAN DIEGO CA 92122-1247